Indeed, inhibition of EFGR/Src/Akt signaling with EFGR inhibitor gefitinib, Src inhibitor dasatinib, and Akt inhibitor LY294002 specifically decreased SOX2 expression in NSCLC H1650SP-Adh CSCs [478]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.